Editorial Board
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 1, 2024 Category: Cardiology Source Type: research
Table of Contents
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 1, 2024 Category: Cardiology Source Type: research
Masthead
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 1, 2024 Category: Cardiology Source Type: research
The Heart as a Reminder for Oneness
What does JCF stand for? What is its brand? Who does it cater to? (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 1, 2024 Category: Cardiology Authors: ANURADHA LALA, MEREDITH T. HURT, ROBERT J. MENTZ Tags: Editor's Page: We've been thinking … Source Type: research
A Board of Our Own: The New American Board for Cardiovascular Medicine
The Heart Failure Society of America has joined with the American College of Cardiology, the American Heart Association, the Heart Rhythm Society, and the Society for Cardiovascular Angiography& Interventions to propose a new board of cardiovascular medicine that would be an independent, self-governed entity, committed to sustained value for cardiovascular professionals and service to patients and the public. This new cardiovascular medicine board will be distinct from the American Board of Internal Medicine, which has historically been the umbrella board for cardiovascular medicine. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - February 1, 2024 Category: Cardiology Authors: JAMES C. FANG Tags: HFSA President's Message Source Type: research
Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have emerged as promising agents to improve outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. GLP-1 is an incretin hormone produced endogenously by the gut in response to food intake that augments insulin release and inhibits glucagon secretion, thereby reducing hepatic glucose production. As such, GLP-1RA were developed for glycemic control in patients with diabetes, with the first approval in 2005. In addition, GLP-1 agonists delay gastric emptying and inhibit appetite, resulting in decreased food intake and weight loss. (Sour...
Source: Journal of Cardiac Failure - January 30, 2024 Category: Cardiology Authors: Elissa Driggin, Parag Goyal Tags: Perspectives Source Type: research
Patient Focus: Sodium-Glucose Cotransporter-2 Inhibitor Rates for Patients with Heart Failure in the Veterans Affairs Health System. We Need to Move the Needle! An explanation of “Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Hospitalized Patients with Heart Failure: Insights from the Veterans Affairs Healthcare System”
In this issue of the Journal of Cardiac Failure, Dr. Anubodh Varshney and colleagues explore what influences the likelihood of prescription for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) for United States ’ military veterans hospitalized with heart failure at Veteran's Affairs hospitals. SGLT2i are a relatively new class of medications that have been proven to reduce the chances of dying or being hospitalized due to heart failure.1,2 SGLT2i include medicines like dapagliflozin, empagliflozin, canag liflozin, and ertugliflozin. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 26, 2024 Category: Cardiology Authors: Nicholas S. Hendren, Jennifer T. Thibodeau Source Type: research
A Single-Center Analysis of Palliative-Care Clinician Contact Following Declination of Advanced Heart Failure Therapy
In 2013, the Center for Medicare and Medicaid Services (CMS) issued a National Coverage Determination that made palliative-care involvement a requirement for those considered for left ventricular assist devices (LVADs) as destination therapy.1 In response, many advanced heart failure (HF) therapy programs began incorporating palliative-care consultations into their LVAD and heart transplant (HT) workflow. Despite this, the incorporation of palliative-care clinicians in the earlier stages of HF care remains lacking. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 25, 2024 Category: Cardiology Authors: Kolby Johnson, Leigh Vaughan, Jennifer Dulin, Elizabeth Higgins, Abigail Southard Source Type: research
Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the veterans affairs healthcare system
The use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in Veteran Affairs (VA) patients hospitalized with heart failure (HF) has not been previously reported. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 25, 2024 Category: Cardiology Authors: Anubodh S. Varshney, Jamie Calma, Neil M. Kalwani, Stephanie Hsiao, Karim Sallam, Fang Cao, Natasha Din, Jessica Schirmer, Ankeet S. Bhatt, Andrew P. Ambrosy, Paul Heidenreich, Alexander T. Sandhu Source Type: research
A Single Center Analysis of Palliative Care Clinician Contact Following Declination from Advanced Heart Failure Therapy
In 2013 the Center for Medicare and Medicaid Services (CMS) issued a National Coverage Determination that made palliative care involvement a requirement for those considered for Left Ventricular Assist Devices (LVADs) as a destination therapy.1 In response, many advanced heart failure therapy programs began incorporating palliative care consults into their LVAD and heart transplant (HT) workflow. Despite this, incorporation of palliative care clinicians into the earlier stages of heart failure care remains lacking. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 25, 2024 Category: Cardiology Authors: Kolby Johnson, Leigh Vaughan, Jennifer Dulin, Elizabeth Higgins, Abigail Southard Source Type: research
Advanced Heart Failure and Transplant Cardiology as a New Subspecialty in Latin America: Challenges and Opportunities Based on a Brazilian Survey Study
Advanced Heart Failure and Transplant Cardiology (AHFTC) subspecialty is well established in Europe and in the United States within the cardiology practice (1,2). In Brazil, there is no formal certification of the HF subspecialty, and structured AHFTC training programs are relatively new, despite its existence for over 20 years as a dynamic and proactive HF department as part of the Brazilian Society of Cardiology (SBC) (3). As such, compared to other countries, Brazil is at a much earlier stage in the development of the HF subspecialty. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 21, 2024 Category: Cardiology Authors: Rafaela Vebber Bisol, Nadine Clausell, Jefferson L. Vieira, Fernando Bacal, Renato D. Lopes, Livia Adams Goldraich Tags: Research Letter Source Type: research
With Great Data Come Great Responsibilities: The Cardiac Amyloidosis Registry Study
The landscape of cardiac amyloidosis (CA) has changed dramatically over the last decade. Once perceived as a rare condition, CA is now recognized as an underdiagnosed cause of heart failure associated with significant morbidity and mortality. Once heart failure ensues, light chain (AL)- and transthyretin (ATTR)-CA are highly fatal if left untreated, with a median survival of less than 1 year and 4 years, respectively [1]. Advances in cardiac imaging, including speckle-tracking echocardiography, cardiac magnetic resonance, and bone tracer nuclear scintigraphy to identify the disease, have been fundamental to our understandi...
Source: Journal of Cardiac Failure - January 18, 2024 Category: Cardiology Authors: Jennifer Maning, Sanjiv J. Shah, Ravi B. Patel Tags: Editorial Comment Source Type: research
Blood pressure response and symptoms during active standing test among hospitalized and outpatients with heart failure: results from the GRAVITY-HF prospective observational cohort study
Orthostatic hypotension (OH) and orthostatic hypertension (OHtn) characterize opposite forms of excessive blood pressure (BP) change during orthostatic stress. Regardless of the change directionality, both responses are common in general population with an average prevalence of 30%1 and independently associated with morbidity, all-cause mortality and major cardiovascular events, including a two-fold higher risk of incident heart failure (HF)2 –4. A number of mechanisms link the inability to maintain normotension at standing and HF including shared pathophysiology mediated by volume changes, autonomic dysregulation and li...
Source: Journal of Cardiac Failure - January 17, 2024 Category: Cardiology Authors: Anzhela Soloveva, Darya Fedorova, Marat Fudim, Nadezhda Vinogradova, Alena Chemodanova, Anastasia Kozlova, Igor Fomin, Mariya Skuratova, Natalia Shneidmiller, Galina Golovina, Elena Kosmacheva, Ekaterina Gubareva, Marina Teterina, Elena Godunko, Anna Ches Source Type: research
The Veterans Affairs ’ Dashboard Confessional: Vindication of the VA HF Dashboard
Recent reports on heart failure (HF) epidemiology and outcomes highlight that approximately 6.7 million Americans have HF. The lifetime risk of HF for adults in the United States is 24%, with increasing incidence and burden of HF risk factors, such as hypertension, obesity, and health inequities.[1] HF is associated with substantial economic burden, and health care related expenditure for the disease is increasing at a more rapid pace compared to other chronic conditions such as type 2 diabetes mellitus and cancer. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 10, 2024 Category: Cardiology Authors: Melissa Lyle, Mark N. Belkin Tags: Editorial Comment Source Type: research
A Reason to be Positive: Early Cardiac Allograft Vasculopathy and Acute Rejection in Recipients of HCV+ Donor Hearts
The increasing transplantation of hepatitis C virus (HCV) nucleic acid test (NAT) positive hearts in the contemporary era of direct-acting antiviral (DAA) therapy has been a critical, practical approach to expanding the donor pool for life-saving heart transplantation (1). While short term graft and patient survival has been established to be non-inferior to that of recipients of HCV NAT- organs, historical data had suggested an increased risk of cardiac allograft vasculopathy (CAV) among recipients of organs from HCV seropositive donors (2-4). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 10, 2024 Category: Cardiology Authors: Laura DiChiacchio, Andrew R Higgins Tags: Editorial Comment Source Type: research
